Aktiesnakken — December 2014
-
Genmab vil også drøfte dets prækliniske pipeline og de egenudviklede teknologier DuoBody
og HexaBody
samt præsentere selskabets hovedmålsætninger for 2015. -
mornings
-
-
-
København, Danmark; 4. december 2014 — Genmab A/S (OMX: GEN) har i dag meddelt, at selskabets samarbejdspartner Janssen Biotech, Inc. (Janssen) planlægger at igangsætte et fase II studie med daratumumab til behandling af non-Hodgkins lymfomer (NHL). I studiet (LYM2001) evalueres daratumumab som monoterapi til behandling af tre forskellige former for NHL: diffust storcellet B-celle lymfom (DLBCL), follikulært lymfom (FL) og mantle-celle lymfom (MCL). Patientrekruttering til studiet ventes igangsa
-
godmorgen
-
-
@Repsac & Hegu: ser godt ud for laks, men det også om at være vaks. Vi ser hvordan det går gamle udbyttekonger pt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind